医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

To Accelerate Research on Anti-aging and Age-related Disease,In Light of the Near Future of a Super-aging Society,Notice of Transfer of Hakushindo Pharmaceutical Co., Ltd. Shares

2018年03月21日 AM12:30
このエントリーをはてなブックマークに追加


 

TOKYO

Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo, CEO Daizo Shimamura) provided research funding to the Project Research Center For Clinical Trials and Preventative Medicine at the Hiroshima University Graduate School of Biomedical & Health Sciences to carry out the world’s first clinical study regarding long-term (24 weeks) oral intake of NMN (β-nicotinamide mononucleotide). The name of the trial is: Evaluation of the effects of long-term ingestion of nicotinamide mononucleotide (NMN). The purpose of the trial is to confirm an increase in rejuvenating hormones, activation of mitochondria, and to confirm the emergence of sirtuin genes 1 and 2.
Hakushindo Pharmaceutical has recently transferred all of its shares to Shinkowa Pharmaceutical Co., Ltd. (head office: Chuo-ku, Tokyo, CEO, Megumi Tanaka).

The clinical trial on oral NMN intake is currently underway at the Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine.
UMIN trial ID: UMIN000025739
http://rctportal.niph.go.jp/en/detail?trial_id=UMIN000025739

The NMN source used in the clinical trial at the Hiroshima University Graduate School of Biomedical & Health Sciences: Project Research Center For Clinical Trials and Preventative Medicine was purchased from Shinkowa Pharmaceutical Co., Ltd., and the completion of Hakushindo Pharmaceutical’s defined role in this clinical trial is the reason for the transfer of the company’s shares to Shinkowa Pharmaceutical Co., Ltd.

In the future, Hakushindo Pharmaceutical intends to actively carry out new clinical studies of NMN, as well as other related clinical studies.

Company profile
Company name: Hakushindo Pharmaceutical Co., Ltd.
Representative: Daizo Shimamura
Location: Shinjuku-ku, Tokyo
Business description: Health food and cosmetics sales business, clinical research consignment

View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005617/en/

CONTACT

For inquiries related to this matter
Hakushindo Pharmaceutical Co.,
Ltd.
Daizo Shimamura, +81-3-5322-2868
Fax: +81-3-5322-2869
shimamura@hsd-japan.com
*
Please make all inquiries by email.

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
  • 内布拉斯加大学医学中心和阿南达宣布,FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验
  • Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
  • Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for Use of Its Probiotic Bifidobacterium longum BB536 in Infant and Toddler Foods
  • MSITEK Sponsors a Hospice IT and Digital Project in India as Part of CSR (Corporate Social Responsibility) Initiatives